Format

Send to

Choose Destination
J Neuroimmunol. 2013 Dec 15;265(1-2):82-90. doi: 10.1016/j.jneuroim.2013.10.003. Epub 2013 Oct 12.

The effects of teriflunomide on lymphocyte subpopulations in human peripheral blood mononuclear cells in vitro.

Author information

1
BioInnovation Group, Sanofi, Cambridge, MA, USA.

Abstract

Teriflunomide is an inhibitor of dihydro-orotate dehydrogenase (DHODH), and is hypothesized to ameliorate multiple sclerosis by reducing proliferation of stimulated lymphocytes. We investigated teriflunomide's effects on proliferation, activation, survival, and function of stimulated human peripheral blood mononuclear cell subsets in vitro. Teriflunomide had little/no impact on lymphocyte activation but exerted significant dose-dependent inhibition of T- and B-cell proliferation, which was uridine-reversible (DHODH-dependent). Viability analyses showed no teriflunomide-associated cytotoxicity. Teriflunomide significantly decreased release of several pro-inflammatory cytokines from activated monocytes in a DHODH-independent fashion. In conclusion, teriflunomide acts on multiple immune cell types and processes via DHODH-dependent and independent mechanisms.

KEYWORDS:

Anti-inflammatory; Anti-proliferative; CNS; De novo pyrimidine synthesis; Immunomodulation; Multiple sclerosis

PMID:
24182769
DOI:
10.1016/j.jneuroim.2013.10.003
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center